BR112022005666A2 - Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso - Google Patents
Compostos engatadores de nk que se ligam a antígenos virais e métodos de usoInfo
- Publication number
- BR112022005666A2 BR112022005666A2 BR112022005666A BR112022005666A BR112022005666A2 BR 112022005666 A2 BR112022005666 A2 BR 112022005666A2 BR 112022005666 A BR112022005666 A BR 112022005666A BR 112022005666 A BR112022005666 A BR 112022005666A BR 112022005666 A2 BR112022005666 A2 BR 112022005666A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- domain
- viral antigens
- binding compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 abstract 3
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
compostos engatadores de nk que se ligam a antígenos virais e métodos de uso. a presente invenção refere-se a compostos que envolvem células nk e métodos de utilização dos compostos. geralmente, o composto inclui um domínio de engate de nk, um domínio de direcionamento que se liga seletivamente a uma célula alvo e um domínio de ativação de nk que liga operacionalmente o domínio de engate de nk e o domínio de direcionamento. em uma modalidade ilustrativa, o domínio de direcionamento se liga seletivamente a um antígeno de hiv.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962906660P | 2019-09-26 | 2019-09-26 | |
PCT/US2020/052671 WO2021062119A1 (en) | 2019-09-26 | 2020-09-25 | Nk engager compounds that bind viral antigens and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005666A2 true BR112022005666A2 (pt) | 2022-06-21 |
Family
ID=75166466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005666A BR112022005666A2 (pt) | 2019-09-26 | 2020-09-25 | Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220363737A1 (pt) |
EP (1) | EP4041757A4 (pt) |
JP (1) | JP2022549494A (pt) |
KR (1) | KR20220069026A (pt) |
CN (1) | CN114502577A (pt) |
AU (1) | AU2020354654A1 (pt) |
BR (1) | BR112022005666A2 (pt) |
CA (1) | CA3151281A1 (pt) |
IL (1) | IL291646A (pt) |
WO (1) | WO2021062119A1 (pt) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676091B (zh) * | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
EP3359168A4 (en) * | 2015-10-06 | 2019-08-07 | Regents of the University of Minnesota | THERAPEUTIC COMPOUNDS AND METHODS |
EP3525821A4 (en) * | 2016-10-17 | 2020-09-09 | University of Maryland | MULTI-SPECIFIC ANTIBODIES TARGETING THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR METHODS OF USE |
AU2017345791B2 (en) * | 2016-10-21 | 2020-10-22 | Altor Bioscience Corporation | Multimeric IL-15-based molecules |
EP4204092A1 (en) * | 2020-08-25 | 2023-07-05 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
-
2020
- 2020-09-25 CA CA3151281A patent/CA3151281A1/en active Pending
- 2020-09-25 EP EP20870067.4A patent/EP4041757A4/en active Pending
- 2020-09-25 BR BR112022005666A patent/BR112022005666A2/pt unknown
- 2020-09-25 JP JP2022519141A patent/JP2022549494A/ja active Pending
- 2020-09-25 AU AU2020354654A patent/AU2020354654A1/en active Pending
- 2020-09-25 US US17/762,354 patent/US20220363737A1/en active Pending
- 2020-09-25 CN CN202080067868.7A patent/CN114502577A/zh active Pending
- 2020-09-25 KR KR1020227011781A patent/KR20220069026A/ko active Search and Examination
- 2020-09-25 WO PCT/US2020/052671 patent/WO2021062119A1/en unknown
-
2022
- 2022-03-23 IL IL291646A patent/IL291646A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020354654A1 (en) | 2022-04-14 |
EP4041757A4 (en) | 2024-04-17 |
IL291646A (en) | 2022-05-01 |
CA3151281A1 (en) | 2021-04-01 |
KR20220069026A (ko) | 2022-05-26 |
CN114502577A (zh) | 2022-05-13 |
US20220363737A1 (en) | 2022-11-17 |
WO2021062119A1 (en) | 2021-04-01 |
EP4041757A1 (en) | 2022-08-17 |
JP2022549494A (ja) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
BR112019014986A8 (pt) | Anticorpo que alveja bcma e uso do mesmo | |
BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
PH12018500766A1 (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
UY36538A (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
BR112018006811A2 (pt) | compostos terapêuticos e métodos | |
CR20110035A (es) | Composiciones y Métodos para Anticuerpos que se dirigen a la Proteína de Complemento C5 | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
CO2020012360A2 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
BR112018075653A2 (pt) | anticorpos anti-b7-h3 e conjugados anticorpo fármaco | |
BR112017019617A2 (pt) | Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada | |
CL2011000117A1 (es) | Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. | |
AR082630A1 (es) | Anticuerpos anti-tenascina-c a2 y metodos de uso | |
BR112019004995A2 (pt) | anticorpo que se liga especificamente a pd-1 e fragmento funcional do mesmo | |
BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
MX2019010797A (es) | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. |